Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma Clinical Trial

Official title:

Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06271057
• Other study ID #: CARMOD
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 22, 2024
• Est. completion date: October 20, 2027

Study information

• Verified date: February 2024
• Source: The Lymphoma Academic Research Organisation
• Contact: Stéphanie DOYEN
• Phone: +33 4 27 01 27 36
• Email: stephanie.doyen[@]lysarc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first.

Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study.

The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion.

The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 65
• Est. completion date: October 20, 2027
• Est. primary completion date: January 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted

2. Adults patients (= 18-year-old at the time of signing the informed consent form; no upper age limit)

3. Eligible for any commercialized market authorized anti-CD19 CAR T-cells

4. Performance Status 0 or 1

5. With aggressive large B-cell lymphoma, including:

• diffuse large B-cell lymphoma

• Primary mediastinal B-cell lymphoma

• Any transformed follicular or marginal zone lymphoma

• high-grade B-cell lymphoma (HGBL) Note: patients with Central Nervous System (CNS) involvement could be included but not patients with primary CNS lymphoma

6. Available biopsy for centralized review

7. With a CAR T-cells indication as soon as 2nd line treatment no later than in 4th line, previously validated by the multidisciplinary tumor board Note: Any treatment performed prior to leukapheresis is considered a line of treatment

8. Total MetabolicTumor Volume (TMTV) > 80 ml, measured by centralized review, on 18FDG-PET (positron emission tomography) done just before starting CAR T-cells procedure (i.e., D-13 +/- 4 days before CAR-T cells infusion)

9. Creatinine clearance (as estimated by Modification of Diet in Renal Disease (MDRD) if > 60-year-old or Cockcroft-Gault if <60yo) >45 mL/min,

10. Adequate hepatic function:

• aspartate aminotransferase/alanine aminotransferase (ALT/AST) = 3.0 x ULN. (Note:

In the case of documented liver involvement by lymphoma, ALT/AST must be = 5.0 x ULN)

• Serum total bilirubin = 2.0 mg/dL (34 µmol/L) (Note: In the case of Gilbert's syndrome, or documented liver or pancreatic involvement by lymphoma, serum total bilirubin must be = 3.0 mg/dL (51 µmol/L))

11. Patient covered by any social security system (France)

12. Patient who understands and speaks one of the country official languages, unless local regulation authorizes independent translators

13. Contraception:

• For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, as soon as consent is signed, during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide, Women must refrain from donating eggs during this same period.

Exclusion Criteria:

1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease free for at least 3 years

2. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the sponsor's medical monitor

3. History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection; subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines

4. Significant pulmonary function impairment and oxygen saturation (SaO2) < 92% on room air

5. Significant cardiovascular disease such as New York Heart Association Class III or IV or Objective Class C or D cardiac disease (see appendix 07)

6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment

7. History of severe immediate hypersensitivity reaction to any of the agents used in this study

8. Current treatment with strong CYP3A4/5 modulators (see appendix 13)

9. Pregnant, planning to become pregnant or lactating Women of Child Bearing Potential

10. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision)

11. Person deprived of his/her liberty by a judicial or administrative decision

12. Person hospitalized without consent

13. Adult person under legal protection

Related Conditions & MeSH terms

• Diffuse Large B-cell Lymphoma Refractory
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Refractory High Grade B-Cell Lymphoma
• Refractory Transformed B-cell Non-Hodgkin Lymphoma

Intervention

Drug:
• golcadomide
golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166

Locations

Country	Name	City	State
France	Hopital Henri Mondor	Créteil
France	Chu Dijon Bourgogne	Dijon
France	Chu de Grenoble	La Tronche
France	Chru de Lille	Lille
France	Institut Paoli Calmettes	Marseille
France	Chu de Montpellier	Montpellier
France	Chu de Nantes	Nantes
France	Hopital Saint-Louis	Paris
France	Chu de Bordeaux	Pessac
France	Chu Pontchaillou	Rennes
France	Centre Henri Becquerel	Rouen
France	Iuct Oncopole	Toulouse
France	Chu Brabois	Vandœuvre-lès-Nancy

Sponsors (2)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation	Lymphoma Study Association

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete metabolic response rate (CMR rate)	efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion	3 months
Secondary	Objective response rate (ORR)	incidence of either a complete (CMR) or a partial (PMR) metabolic response per the Lugano Classification (Cheson 2014) as determined by study investigators	at 1 month, 3 months, 6 months, 1 year and 2 years, from CAR-T infusion
Secondary	Objective response rate (ORR)	determined by imaging central review	at 1 month and 3 months
Secondary	Complete response rate (CRR)	percentage of complete response determined by investigator assessment classification	at 1 Month, 6 Months, 1 year, and 2 years
Secondary	Duration of response (DR)	time from attainment of PMR or CMR to the date of first documented disease progression/relapse (based on investigator disease assessment (INV)) or death from any cause	2 years
Secondary	Event-free survival (EFS)	the time between CAR T-cells injection and death, disease progression, or start of subsequent new anti-lymphoma therapy including Stem Cell Transplant (SCT)	2 years
Secondary	Progression-free survival (PFS)	time from CAR T-cells injection to the first observation of documented disease progression/relapse (based on investigator disease assessment (INV)) or death	2 years
Secondary	Time To Next anti-Lymphoma Treatment (TTNLT)	from the date of CAR T-cells injection to the date of first documented administration of any new anti-lymphoma treatment	2 years
Secondary	Overall survival (OS)	from date of CAR T-cells injection to the date of death	2 years
Secondary	Incidence of Adverse Events and Serious Adverse events		2 years